Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2b pediatric letermovir prophylaxis after allogeneic HSCT
MOH_2019-04-28_007099Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of letermovir in cytomegalovirus disease (CMV), sponsored by Merck & Co. Primary endpoints: Pharmacokinetics of letermovir, Safety of letermovir and 2 more. Started Jan 2019; status: active, not recruiting.
02
Drugs
letermovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on MOH_2019-04-28_007099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-04-28_007099.